Examination of the Effectiveness of Local Therapy for Oligo-recurrence of EGFR-mutated NSCLC

Overview

Journal Thorac Cancer

Specialties Oncology
Pulmonary Medicine

Date 2023 Jan 31

PMID 36720507

Authors

Dai Sonoda

Yasuto Kondo

Raito Maruyama

Shoko Hayashi

Masahito Naito

Masashi Mikubo

Yoshio Matsui

Kazu Shiomi

Yukitoshi Satoh

Affiliations

Soon will be listed here.

Abstract

Background: The effectiveness of local therapy has been reported in patients with oligo-recurrence of non-small cell lung cancer (NSCLC), a metachronous recurrence with a limited number of recurrences, which can be treated with local therapy. Conversely, remarkable progress has been made in systemic therapy for NSCLC with the advent of molecular targeted therapy. In particular, epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are very effective in the treatment of EGFR-mutated NSCLC. There is currently no consensus on treatment for oligo-recurrence of EGFR-mutated NSCLC.

Methods: From 2004 to 2014, 811 patients underwent complete resection for NSCLC at Kitasato University Hospital and, of these, 244 patients developed recurrence. Oligo-recurrence was defined as the presence of two or less recurrent lesions, and 34 patients presented with EGFR-mutated oligo-recurrence.

Results: We retrospectively examined and compared the effects of EGFR-TKIs with those of radical local therapy in patients with oligo-recurrent EGFR-mutated NSCLC. The five-year post-recurrence survival (PRS) rates of patients with EGFR-mutated oligo-recurrence who received radical local therapy (n = 23) and those who did not (n = 11) were 59.4 and 45.5%, respectively (p = 0.777). Multivariate analysis revealed no favorable prognostic factors associated with prolonged PRS, and radical local therapies did not improve PRS in patients with oligo-recurrence (p = 0.551).

Conclusion: Radical local therapy did not affect PRS in patients with oligo-recurrent EGFR-mutated NSCLC. Even in cases of oligo-recurrence, the administration of local therapy in patients with EGFR-mutated NSCLC might be carefully considered.

Citing Articles

Oligo-Recurrence in Lung Cancer; The Most Curable State Among Advanced Disease?.

Shimada Y Cancers (Basel). 2024; 16(23).

PMID: 39682272 PMC: 11639969. DOI: 10.3390/cancers16234086.

Prognostic factors after radical local therapy for oligo-recurrence of non-small cell lung cancer.

Sonoda D, Kondo Y, Maruyama R, Naito M, Mikubo M, Shiomi K Gen Thorac Cardiovasc Surg. 2024; .

PMID: 39313740 DOI: 10.1007/s11748-024-02084-0.

Prognostic Impact of Postoperative Recurrence in Patients With Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer.

Morita M, Ono A, Sekikawa M, Doshita K, Miura K, Kodama H Cancer Rep (Hoboken). 2024; 7(9):e70004.

PMID: 39245880 PMC: 11381551. DOI: 10.1002/cnr2.70004.

Complex situations in lung cancer: multifocal disease, oligoprogression and oligorecurrence.

Werner R, Steinmann N, Decaluwe H, Date H, De Ruysscher D, Opitz I Eur Respir Rev. 2024; 33(172).

PMID: 38811031 PMC: 11134198. DOI: 10.1183/16000617.0200-2023.

Optimal Treatment Strategy for Oligo-Recurrence Lung Cancer Patients with Driver Mutations.

Tachibana T, Matsuura Y, Ninomiya H, Ichinose J, Nakao M, Okumura S Cancers (Basel). 2024; 16(2).

PMID: 38275904 PMC: 10814831. DOI: 10.3390/cancers16020464.

References

Taylor M, Nagji A, Bhamidipati C, Theodosakis N, Kozower B, Lau C . Tumor recurrence after complete resection for non-small cell lung cancer. Ann Thorac Surg. 2012; 93(6):1813-20. DOI: 10.1016/j.athoracsur.2012.03.031. View

Sakamoto J, Sonobe M, Kobayashi M, Ishikawa M, Kikuchi R, Nakajima D . Prognostic factors for patients in postoperative brain metastases from surgically resected non-small cell lung cancer. Int J Clin Oncol. 2012; 19(1):50-6. DOI: 10.1007/s10147-012-0503-8. View

Gao X, Zhang K, Tang M, Zhang K, Fang L, Liu W . Pooled analysis for surgical treatment for isolated adrenal metastasis and non-small cell lung cancer. Interact Cardiovasc Thorac Surg. 2016; 24(1):1-7. DOI: 10.1093/icvts/ivw321. View

Niibe Y, Nishimura T, Inoue T, Karasawa K, Shioyama Y, Jingu K . Oligo-recurrence predicts favorable prognosis of brain-only oligometastases in patients with non-small cell lung cancer treated with stereotactic radiosurgery or stereotactic radiotherapy: a multi-institutional study of 61 subjects. BMC Cancer. 2016; 16(1):659. PMC: 4992231. DOI: 10.1186/s12885-016-2680-8. View

Goss G, Tsai C, Shepherd F, Bazhenova L, Lee J, Chang G . Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2016; 17(12):1643-1652. DOI: 10.1016/S1470-2045(16)30508-3. View

Sequist L, Yang J, Yamamoto N, OByrne K, Hirsh V, Mok T . Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013; 31(27):3327-34. DOI: 10.1200/JCO.2012.44.2806. View

Matsuguma H, Nakahara R, Wakamatsu I, Kishikawa T, Sugiyama T, Nakamura Y . Definitive Local Therapy for Oligo-recurrence in Patients With Completely Resected Non-small Cell Lung Cancer. Am J Clin Oncol. 2019; 43(3):210-217. DOI: 10.1097/COC.0000000000000656. View

Niibe Y, Yamamoto T, Onishi H, Yamashita H, Katsui K, Matsumoto Y . Pulmonary Oligometastases Treated by Stereotactic Body Radiation Therapy: A Nationwide Survey of 1,378 Patients. Anticancer Res. 2020; 40(1):393-399. DOI: 10.21873/anticanres.13965. View

Postmus P, Brambilla E, Chansky K, Crowley J, Goldstraw P, Patz Jr E . The IASLC Lung Cancer Staging Project: proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancer. J Thorac Oncol. 2007; 2(8):686-93. DOI: 10.1097/JTO.0b013e31811f4703. View

10.

Niibe Y, Kenjo M, Kazumoto T, Michimoto K, Takayama M, Yamauchi C . Multi-institutional study of radiation therapy for isolated para-aortic lymph node recurrence in uterine cervical carcinoma: 84 subjects of a population of more than 5,000. Int J Radiat Oncol Biol Phys. 2006; 66(5):1366-9. DOI: 10.1016/j.ijrobp.2006.07.1384. View

11.

Niibe Y, Kuranami M, Matsunaga K, Takaya M, Kakita S, Hara T . Value of high-dose radiation therapy for isolated osseous metastasis in breast cancer in terms of oligo-recurrence. Anticancer Res. 2009; 28(6B):3929-31. View

12.

Yang J, Wu Y, Schuler M, Sebastian M, Popat S, Yamamoto N . Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015; 16(2):141-51. DOI: 10.1016/S1470-2045(14)71173-8. View

13.

Martin J, Ginsberg R, Venkatraman E, Bains M, Downey R, Korst R . Long-term results of combined-modality therapy in resectable non-small-cell lung cancer. J Clin Oncol. 2002; 20(8):1989-95. DOI: 10.1200/JCO.2002.08.092. View

14.

Yano T, Haro A, Yoshida T, Morodomi Y, Ito K, Shikada Y . Prognostic impact of local treatment against postoperative oligometastases in non-small cell lung cancer. J Surg Oncol. 2010; 102(7):852-5. DOI: 10.1002/jso.21750. View

15.

Moriya T, Hamaji M, Yoshizawa A, Miyata R, Noguchi M, Tamari S . Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors as a first-line treatment for postoperative recurrent and EGFR-mutated non-small-cell lung cancer. Interact Cardiovasc Thorac Surg. 2021; 34(3):416-423. PMC: 8860430. DOI: 10.1093/icvts/ivab283. View

16.

Sonoda D, Kondo Y, Maruyama R, Hayashi S, Naito M, Mikubo M . Examination of the effectiveness of local therapy for oligo-recurrence of EGFR-mutated NSCLC. Thorac Cancer. 2023; 14(8):766-772. PMC: 10008676. DOI: 10.1111/1759-7714.14805. View

17.

Endo C, Sakurada A, Notsuda H, Noda M, Hoshikawa Y, Okada Y . Results of long-term follow-up of patients with completely resected non-small cell lung cancer. Ann Thorac Surg. 2012; 93(4):1061-8. DOI: 10.1016/j.athoracsur.2012.01.004. View

18.

Hishida T, Yoshida J, Aokage K, Nagai K, Tsuboi M . Postoperative oligo-recurrence of non-small-cell lung cancer: clinical features and survival†. Eur J Cardiothorac Surg. 2015; 49(3):847-53. DOI: 10.1093/ejcts/ezv249. View

19.

Martini N, Melamed M . Multiple primary lung cancers. J Thorac Cardiovasc Surg. 1975; 70(4):606-12. View

20.

Han S, Cho S, Yum S, Kim K, Jheon S . Surgical treatment of pulmonary oligorecurrence after curative resection for non-small-cell lung cancer. Interact Cardiovasc Thorac Surg. 2019; 30(1):18-23. DOI: 10.1093/icvts/ivz221. View